Wahler, S.; Müller, A.; Koll, C.; Seyed-Abbaszadeh, P.; Von Der Schulenburg, J.M.
(London : Taylor & Francis Group, 2020)
Background: Adjuvant treatment options have become the standard therapy for stage III and IV resectable cutaneous melanoma. Two recent studies led to the registration of dabrafenib and trametinib as targeted therapies for ...